CD8A and primary biliary cholangitis: Moreover, this paper summarizes current progress and unresolved issues related to putative or emerging targeted therapeutic strategies in PBC, including IL-17 pathway inhibition, CD8<sup>+</sup> T-cell-directed approaches, γδ T-cell modulation, and combination immunotherapy, most of which remain preclinical or indirectly supported in PBC.